Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

By D. Freeman, J. Norrie, N. Sattar, R. Neely, S. Cobbe, Ian Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop and 3 more. Circulation, 2001

921 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/16d1a42ac517910848789e7ebe345af107688ee9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. F. B. Hu
2. J. Pickup
3. JoAnn E. Manson
4. S. Kahn
5. N. Rifai
6. P. Ridker
7. W. Willett
8. Vasanti S. Malik

In Epidemiology

1. J. Pickup
2. F. B. Hu
3. JoAnn E. Manson
4. James B. Meigs
5. N. Rifai
6. P. Ridker
7. Peter Libby
8. B. K. Pedersen

In Surgery

1. J. Pickup
2. F. B. Hu
3. S. Kahn
4. James B. Meigs
5. JoAnn E. Manson
6. N. Rifai
7. J. Tobert
8. P. Ridker

Citations in the corpus

• Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. (2004, background): “Therapy with statins(51) or angiotensin-converting enzyme (ACE) inhibitors(52) improves insulin sensitivity and endothelial dysfunction and, in secondary analyses of CVD prevention studies, has been associated with an approximately 30% reduced risk of incident diabetes.(53,54) However, whether ameli”
• Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, methodology): “analysis of WOSCOPS (West of Scotland Prevention Study).(110) Of 5974 patients without diabetes mellitus at baseline, 57 of 2999 (1.”
• C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. (2002, methodology): “72) (7) but, probably because there are fewer cases, just fails to reach significance at the P 0.”
• The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes (2003, background): “The recent post-hoc analyses showing a possible protective effect on the development of diabetes of the ACE inhibitor ramipril [163] and the HMG CoA reductase inhibitor pravastatin [165] are enticing and emphasise that there are many aspects of the pathogenesis and treatment of the disease that stil”
• Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. (2004, methodology): “Assignment to pravastatin therapy in the West of Scotland Coronary Prevention Study resulted in a 30% reduction in the risk of developing type 2 diabetes (71), perhaps related to the drug’s anti-inflammatory properties.”